Evidence map›Paper›PMID 41125553›Full record

ArticleInternational journal of stem cells2025

The Generation of an Induced Pluripotent Stem Cell Line from a Patient with Phenylketonuria.

Inseon Yu, Heebin Park, Jeongho Lee, Jaemin Jeong

Abstract read
In one paragraph

Article in International journal of stem cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Inseon YuDepartment of Biohealth Convergence, College of Science and Convergence Technology, Seoul Women's University, Seoul, Korea.ORCID https://orcid.org/0000-0001-5610-9986
Heebin ParkDepartment of Biohealth Convergence, College of Science and Convergence Technology, Seoul Women's University, Seoul, Korea.ORCID https://orcid.org/0009-0001-5739-4851
Jeongho LeeDepartment of Pediatrics, Soonchunhyang University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0003-4455-7540
Jaemin JeongDepartment of Biohealth Convergence, College of Science and Convergence Technology, Seoul Women's University, Seoul, Korea.ORCID https://orcid.org/0000-0001-9758-7917

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phenylketonuria (PKU), an autosomal recessive genetic disorder, has been documented to exhibit over 950 distinct mutations. This condition primarily affects the metabolism of phenylalanine, which is affected by a deficiency in the hepatic enzyme phenylalanine hydroxylase. The optimal treatment for PKU disease remains to be determined, necessitating further research. The severity of the disease and the most effective treatment method vary depending on the specific mutation, which necessitates the development of personalized treatment strategies. In this study, we successfully established induced pluripotent stem cell (iPSC) lines from the blood of a PKU patient with the R243Q mutation via Sendai virus-based reprogramming (R243Q-iPSCs). The established R243Q-iPSCs exhibited characteristics of pluripotency, as confirmed through quantitative reverse transcription polymerase chain reaction, western blot, immunocytochemistry, and karyotype analysis. Furthermore, these iPSCs not only successfully differentiated into hepatocytes but also exhibited a complete PKU disease phenotype. These results provide a valuable foundation for PKU disease research, including physiological studies of PKU, gene therapy, drug screening, and the development of platforms for novel cell therapy approaches.

Indexed as

HepatocytesInduced pluripotent stem cellsPhenylalanine hydroxylasePhenylketonurias

Identifiers

PMID41125553
PMCPMC12658155

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.